SGLT2 inhibitors such as dapagliflozin and empagliflozin have been shown to have a significant impact on adipocyte metabolism, energy expenditure, and insulin sensitivity, resulting in weight loss and improved glycemic control in patients with type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.